M. Nakayama

Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data

J. Mahlich, Stephane Cheung, Yukinobu Hamuro, 2018, PloS one.

A comparison of overall survival with 40 and 50mg/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data.

M. Nakayama, K. Fukushima, Hisanori Kobayashi, 2016, Gynecologic oncology.

Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy

T. Miyamoto, M. Kizaki, A. Mori, 2022, International Journal of Hematology.

Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials

M. Nakayama, K. Imanaka, Hisanori Kobayashi, 2016, BMC Urology.

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin

M. Nakayama, K. Fukushima, Yuji Komada, 2015, Hepatology International.

Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan

J. Mahlich, Masateru Okazaki, M. Nakayama, 2018, American journal of men's health.

Hematologists' Preferences for First-line Therapy Characteristics for Multiple Myeloma in Japan: Attribute Rating and Discrete Choice Experiment.

J. Mahlich, Yusuke Nakamura, M. Nakayama, 2018, Clinical therapeutics.

Shared Decision-Making in Patients With Prostate Cancer in Japan: Patient Preferences Versus Physician Perceptions

Hisanori Kobayashi, Hiroji Uemura, Masahiko Nakayama, 2017, Journal of global oncology.